Ozempic
SuccessThe wealthy 1% are turning to new status symbols that can’t be bought—and it’s hurting Dior, Versace, and Burberry
By Emma BurleighDecember 3, 2025
HealthTrump punches new $35 billion hole in national debt with deal for Medicare to cover your Ozempic
By Nick LichtenbergNovember 6, 2025
C-SuiteRay Dalio is backing a $1 billion blueberry unicorn that sells berries nearly the size of golf balls
By Eva RoytburgNovember 4, 2025
HealthAdult obesity rate fell from record high—and big pharma is reaping the benefits from mainstream sales of weight-loss drugs like Zepound and Mounjaro
By Matty Merritt and Morning BrewOctober 31, 2025
By Nick LichtenbergAugust 18, 2025
CommentaryTrump wants Medicare to pay for your Ozempic treatment. Taxpayers may foot the bill for billions in fraud
By Ari Yampolsky and Max VoldmanAugust 12, 2025
NewslettersExclusive: The founders of SoulCycle built a startup for relationships, then pivoted to GLP-1 support groups. Now its assets are being acquired by WeightWatchers
By Emma HinchliffeAugust 7, 2025
C-SuiteNovo Nordisk selects insider Maziar Mike Doustdar as new CEO, to tackle ‘recent market challenges’
By AFPJuly 29, 2025
FinanceNovo Nordisk is losing Canadian patent protection on a blockbuster drug after not paying a small fee
By Jason MaJune 17, 2025
By Naomi Kresge and BloombergMay 16, 2025
HealthCurrency hedging and new U.S. factories: Novo Nordisk CFO thinks Wegovy maker can outmaneuver global trade wars
By Ryan HoggMay 9, 2025
By Marthe Fourcade and BloombergApril 22, 2025
MagazineOzempic and Wegovy pumped $26 billion into Novo Nordisk last year. Can the pharma giant find its next breakthrough before the boom ends?
By Vivienne WaltMarch 31, 2025
By Chris MorrisMarch 7, 2025
